FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3210973670> ?p ?o ?g. }

• W3210973670 endingPage "168" @default.
• W3210973670 startingPage "158" @default.
• W3210973670 abstract "•History of cancer is linked to higher mortality rates due to COVID-19.•Data on the immunogenicity of COVID-19 vaccines in PsC are scarce.•This review included prospective studies that evaluated immunogenicity of vaccines against COVID-19 in PsC.•Vaccination seems overall safe and immunogenic after well-conducted vaccination schedules.•Hematologic patients receiving B-cell-depleting agents in the last 12 months are the most at risk of poor seroconversion. BackgroundCoronavirus disease 2019 (COVID-19) has affected >210 million people worldwide. An optimal therapeutic approach for COVID-19 remains uncertain, to date. Since the history of cancer was linked to higher mortality rates due to COVID-19, the establishment of a safe and effective vaccine coverage is crucial in these patients. However, patients with cancer (PsC) were mostly excluded from vaccine candidates' clinical trials. This systematic review aims to investigate the current available evidence about the immunogenicity of COVID-19 vaccines in PsC.Patients and methodsAll prospective studies that evaluated the safety and efficacy of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were included, with immunogenicity after the first and the second dose as the primary endpoint, when available.ResultsVaccination against COVID-19 for PsC seems overall safe and immunogenic after well-conducted vaccination schedules. Yet the seroconversion rate remains lower, lagged or both compared to the general population. Patients with hematologic malignancies, especially those receiving B-cell-depleting agents in the past 12 months, are the most at risk of poor seroconversion.ConclusionA tailored approach to vaccination may be proposed to PsC, especially on the basis of the type of malignancy and of the specific oncologic treatments received. Coronavirus disease 2019 (COVID-19) has affected >210 million people worldwide. An optimal therapeutic approach for COVID-19 remains uncertain, to date. Since the history of cancer was linked to higher mortality rates due to COVID-19, the establishment of a safe and effective vaccine coverage is crucial in these patients. However, patients with cancer (PsC) were mostly excluded from vaccine candidates' clinical trials. This systematic review aims to investigate the current available evidence about the immunogenicity of COVID-19 vaccines in PsC. All prospective studies that evaluated the safety and efficacy of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were included, with immunogenicity after the first and the second dose as the primary endpoint, when available. Vaccination against COVID-19 for PsC seems overall safe and immunogenic after well-conducted vaccination schedules. Yet the seroconversion rate remains lower, lagged or both compared to the general population. Patients with hematologic malignancies, especially those receiving B-cell-depleting agents in the past 12 months, are the most at risk of poor seroconversion. A tailored approach to vaccination may be proposed to PsC, especially on the basis of the type of malignancy and of the specific oncologic treatments received." @default.
• W3210973670 created "2021-11-08" @default.
• W3210973670 creator A5001814176 @default.
• W3210973670 creator A5003897511 @default.
• W3210973670 creator A5004578546 @default.
• W3210973670 creator A5020254907 @default.
• W3210973670 creator A5022239860 @default.
• W3210973670 creator A5072668656 @default.
• W3210973670 creator A5082291642 @default.
• W3210973670 creator A5089140607 @default.
• W3210973670 date "2022-02-01" @default.
• W3210973670 modified "2023-10-06" @default.
• W3210973670 title "Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review" @default.
• W3210973670 cites W1974369659 @default.
• W3210973670 cites W2034941259 @default.
• W3210973670 cites W2133645992 @default.
• W3210973670 cites W2289579227 @default.
• W3210973670 cites W2917414890 @default.
• W3210973670 cites W2979351891 @default.
• W3210973670 cites W3030573714 @default.
• W3210973670 cites W3034965161 @default.
• W3210973670 cites W3047144258 @default.
• W3210973670 cites W3048620154 @default.
• W3210973670 cites W3082355253 @default.
• W3210973670 cites W3082480386 @default.
• W3210973670 cites W3082648913 @default.
• W3210973670 cites W3084879098 @default.
• W3210973670 cites W3091376205 @default.
• W3210973670 cites W3092131843 @default.
• W3210973670 cites W3092375167 @default.
• W3210973670 cites W3093367571 @default.
• W3210973670 cites W3110466220 @default.
• W3210973670 cites W3116615547 @default.
• W3210973670 cites W3120574399 @default.
• W3210973670 cites W3121008609 @default.
• W3210973670 cites W3123967880 @default.
• W3210973670 cites W3128744449 @default.
• W3210973670 cites W3129692211 @default.
• W3210973670 cites W3131022743 @default.
• W3210973670 cites W3131998187 @default.
• W3210973670 cites W3132886187 @default.
• W3210973670 cites W3134237532 @default.
• W3210973670 cites W3138703198 @default.
• W3210973670 cites W3145657260 @default.
• W3210973670 cites W3149585792 @default.
• W3210973670 cites W3153280867 @default.
• W3210973670 cites W3156866359 @default.
• W3210973670 cites W3157453497 @default.
• W3210973670 cites W3158078097 @default.
• W3210973670 cites W3159505699 @default.
• W3210973670 cites W3162395942 @default.
• W3210973670 cites W3163785571 @default.
• W3210973670 cites W3164216481 @default.
• W3210973670 cites W3164644896 @default.
• W3210973670 cites W3164652662 @default.
• W3210973670 cites W3165224470 @default.
• W3210973670 cites W3165390631 @default.
• W3210973670 cites W3165694484 @default.
• W3210973670 cites W3168511545 @default.
• W3210973670 cites W3170814150 @default.
• W3210973670 cites W3172958999 @default.
• W3210973670 cites W3173150656 @default.
• W3210973670 cites W3173185194 @default.
• W3210973670 cites W3174054271 @default.
• W3210973670 cites W3174790825 @default.
• W3210973670 cites W3175948812 @default.
• W3210973670 cites W3176215631 @default.
• W3210973670 cites W3176668337 @default.
• W3210973670 cites W3176897911 @default.
• W3210973670 cites W3177279996 @default.
• W3210973670 cites W3178694460 @default.
• W3210973670 cites W3182782630 @default.
• W3210973670 cites W3182870240 @default.
• W3210973670 cites W3183003513 @default.
• W3210973670 cites W3183326508 @default.
• W3210973670 cites W3183438352 @default.
• W3210973670 cites W3183558279 @default.
• W3210973670 cites W3183904285 @default.
• W3210973670 cites W3184273969 @default.
• W3210973670 cites W3184922835 @default.
• W3210973670 cites W3186767253 @default.
• W3210973670 cites W3187412067 @default.
• W3210973670 cites W3187473944 @default.
• W3210973670 cites W3188940456 @default.
• W3210973670 cites W3189762432 @default.
• W3210973670 cites W3189962712 @default.
• W3210973670 cites W3190264333 @default.
• W3210973670 cites W3190427561 @default.
• W3210973670 cites W3191931392 @default.
• W3210973670 cites W3193005055 @default.
• W3210973670 cites W3193601449 @default.
• W3210973670 cites W3193784398 @default.
• W3210973670 cites W3194536759 @default.
• W3210973670 cites W3195311678 @default.
• W3210973670 cites W3195990721 @default.
• W3210973670 cites W3197438642 @default.
• W3210973670 cites W3201177512 @default.
• W3210973670 cites W3201834202 @default.

• next